Publications in collaboration with researchers from Maple Leaf Medical Clinic (1)

2009

  1. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

    Journal of Acquired Immune Deficiency Syndromes, Vol. 50, Núm. 5, pp. 474-481